vs

Side-by-side financial comparison of GENCOR INDUSTRIES INC (GENC) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

GENCOR INDUSTRIES INC is the larger business by last-quarter revenue ($23.6M vs $12.5M, roughly 1.9× Avidity Biosciences, Inc.). GENCOR INDUSTRIES INC runs the higher net margin — 14.6% vs -1398.3%, a 1412.9% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -25.0%). GENCOR INDUSTRIES INC produced more free cash flow last quarter ($10.1M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -23.9%).

Gencor Industries Inc is a leading manufacturer of heavy construction and infrastructure equipment, specializing in asphalt production plants, thermal combustion systems, and supporting road-building machinery. It primarily serves North American and global construction markets, supplying products to both public sector infrastructure projects and private commercial construction operators.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

GENC vs RNA — Head-to-Head

Bigger by revenue
GENC
GENC
1.9× larger
GENC
$23.6M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+459.0% gap
RNA
434.0%
-25.0%
GENC
Higher net margin
GENC
GENC
1412.9% more per $
GENC
14.6%
-1398.3%
RNA
More free cash flow
GENC
GENC
$167.0M more FCF
GENC
$10.1M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-23.9%
GENC

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
GENC
GENC
RNA
RNA
Revenue
$23.6M
$12.5M
Net Profit
$3.4M
$-174.4M
Gross Margin
28.7%
Operating Margin
13.2%
-1513.5%
Net Margin
14.6%
-1398.3%
Revenue YoY
-25.0%
434.0%
Net Profit YoY
-9.8%
-117.0%
EPS (diluted)
$0.23
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GENC
GENC
RNA
RNA
Q4 25
$23.6M
Q3 25
$18.8M
$12.5M
Q2 25
$27.0M
$3.8M
Q1 25
$38.2M
$1.6M
Q4 24
$31.4M
$3.0M
Q3 24
$20.9M
$2.3M
Q2 24
$25.6M
$2.0M
Q1 24
$40.7M
$3.5M
Net Profit
GENC
GENC
RNA
RNA
Q4 25
$3.4M
Q3 25
$1.9M
$-174.4M
Q2 25
$3.8M
$-157.3M
Q1 25
$6.1M
$-115.8M
Q4 24
$3.8M
$-102.3M
Q3 24
$1.5M
$-80.4M
Q2 24
$2.6M
$-70.8M
Q1 24
$6.2M
$-68.9M
Gross Margin
GENC
GENC
RNA
RNA
Q4 25
28.7%
Q3 25
24.2%
Q2 25
26.5%
Q1 25
29.7%
Q4 24
27.6%
Q3 24
25.6%
Q2 24
23.9%
Q1 24
30.3%
Operating Margin
GENC
GENC
RNA
RNA
Q4 25
13.2%
Q3 25
-1.2%
-1513.5%
Q2 25
11.6%
-4448.7%
Q1 25
17.0%
-8360.9%
Q4 24
14.7%
-4069.6%
Q3 24
5.9%
-4200.9%
Q2 24
7.8%
-4040.4%
Q1 24
17.4%
-2178.6%
Net Margin
GENC
GENC
RNA
RNA
Q4 25
14.6%
Q3 25
10.2%
-1398.3%
Q2 25
14.2%
-4089.3%
Q1 25
16.0%
-7360.0%
Q4 24
12.1%
-3439.5%
Q3 24
6.9%
-3441.7%
Q2 24
10.0%
-3461.8%
Q1 24
15.3%
-1943.4%
EPS (diluted)
GENC
GENC
RNA
RNA
Q4 25
$0.23
Q3 25
$0.13
$-1.27
Q2 25
$0.26
$-1.21
Q1 25
$0.42
$-0.90
Q4 24
$0.26
$-0.80
Q3 24
$0.10
$-0.65
Q2 24
$0.17
$-0.65
Q1 24
$0.42
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GENC
GENC
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$147.7M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$215.2M
$1.9B
Total Assets
$228.9M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GENC
GENC
RNA
RNA
Q4 25
$147.7M
Q3 25
$136.3M
$350.2M
Q2 25
$136.0M
$243.9M
Q1 25
$143.7M
$254.2M
Q4 24
$130.1M
$219.9M
Q3 24
$115.4M
$370.2M
Q2 24
$116.6M
$575.8M
Q1 24
$117.1M
$471.4M
Total Debt
GENC
GENC
RNA
RNA
Q4 25
Q3 25
$0
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
Q1 24
Stockholders' Equity
GENC
GENC
RNA
RNA
Q4 25
$215.2M
Q3 25
$211.8M
$1.9B
Q2 25
$209.9M
$1.2B
Q1 25
$206.1M
$1.3B
Q4 24
$200.0M
$1.4B
Q3 24
$196.1M
$1.5B
Q2 24
$194.7M
$1.2B
Q1 24
$192.1M
$830.9M
Total Assets
GENC
GENC
RNA
RNA
Q4 25
$228.9M
Q3 25
$222.6M
$2.1B
Q2 25
$220.2M
$1.4B
Q1 25
$223.9M
$1.5B
Q4 24
$218.2M
$1.6B
Q3 24
$208.1M
$1.6B
Q2 24
$201.8M
$1.3B
Q1 24
$206.0M
$951.5M
Debt / Equity
GENC
GENC
RNA
RNA
Q4 25
Q3 25
0.00×
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GENC
GENC
RNA
RNA
Operating Cash FlowLast quarter
$11.1M
$-156.2M
Free Cash FlowOCF − Capex
$10.1M
$-156.9M
FCF MarginFCF / Revenue
43.0%
-1257.6%
Capex IntensityCapex / Revenue
4.1%
5.7%
Cash ConversionOCF / Net Profit
3.23×
TTM Free Cash FlowTrailing 4 quarters
$-3.2M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GENC
GENC
RNA
RNA
Q4 25
$11.1M
Q3 25
$-275.0K
$-156.2M
Q2 25
$-23.9M
$-199.7M
Q1 25
$12.4M
$-124.8M
Q4 24
$14.8M
$-99.9M
Q3 24
$-3.2M
$-65.6M
Q2 24
$-1.0M
$-65.0M
Q1 24
$11.7M
$-70.4M
Free Cash Flow
GENC
GENC
RNA
RNA
Q4 25
$10.1M
Q3 25
$-1.3M
$-156.9M
Q2 25
$-24.4M
$-203.0M
Q1 25
$12.3M
$-128.6M
Q4 24
$14.5M
$-103.8M
Q3 24
$-3.3M
$-67.3M
Q2 24
$-1.4M
$-65.5M
Q1 24
$11.7M
$-71.3M
FCF Margin
GENC
GENC
RNA
RNA
Q4 25
43.0%
Q3 25
-6.8%
-1257.6%
Q2 25
-90.4%
-5277.1%
Q1 25
32.2%
-8174.3%
Q4 24
46.1%
-3491.0%
Q3 24
-15.8%
-2881.8%
Q2 24
-5.6%
-3204.6%
Q1 24
28.7%
-2012.3%
Capex Intensity
GENC
GENC
RNA
RNA
Q4 25
4.1%
Q3 25
5.4%
5.7%
Q2 25
1.8%
86.9%
Q1 25
0.4%
238.6%
Q4 24
1.0%
131.7%
Q3 24
0.4%
72.9%
Q2 24
1.5%
26.0%
Q1 24
0.0%
25.8%
Cash Conversion
GENC
GENC
RNA
RNA
Q4 25
3.23×
Q3 25
-0.14×
Q2 25
-6.24×
Q1 25
2.04×
Q4 24
3.88×
Q3 24
-2.22×
Q2 24
-0.41×
Q1 24
1.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons